The Pharmaceutical Tariff Trump Is Planning Could Hit 200% — Here Is What It Would Do to Medicine Prices

The Trump administration has signaled pharmaceutical tariffs could reach 200% by mid-to-late 2026. Here is what would happen to the price of medicines for American patients and globally.

The Trump administration's signals that pharmaceutical tariffs could potentially rise toward 200 percent by mid-to-late 2026 — currently exempt from tariffs but targeted in a separate review process — represent the most economically consequential single tariff decision in the current trade war context. J.P. Morgan Global Research identified pharmaceutical tariffs as one of the key uncertainties in their trade policy analysis, and for good reason: the global pharmaceutical supply chain is uniquely concentrated in ways that make tariff escalation particularly impactful for American patients.

The specific supply chain concentration: approximately 80 percent of active pharmaceutical ingredients used in the US are manufactured in India and China. The finished drugs that American patients take are typically formulated in India — which has built the world's largest generic pharmaceutical manufacturing industry — or in European facilities, using APIs from India and China. A 200 percent tariff on pharmaceutical imports would add approximately $200 billion to the annual cost of the medicines Americans buy.

For individual patients: a generic medication that currently costs $15 for a 90-day supply would see its import cost alone — before retailer and insurer margins — increase dramatically. The specific pass-through to patients depends on insurance contract structures, formulary management, and the extent to which manufacturers absorb versus pass costs. For uninsured patients and patients on high-deductible plans, the pass-through is most direct and most acute.

For the healthcare system: hospitals, which bulk-purchase generic medications for inpatient use, would face immediate budget impacts. Generic drug shortages — already a persistent problem in the American healthcare system — would likely worsen as higher-cost supply chains become economically impractical for lower-margin generic products.

For Europe, pharmaceutical tariffs on the US market would redirect European pharmaceutical exports toward other markets, potentially tightening European drug supplies as companies prioritise markets with better pricing. The global pharmaceutical supply chain is sufficiently integrated that a tariff of this magnitude would produce visible effects outside the US.